Cohort study to observe asthma outcomes in China
The Cohort Study for Asthma in China: an Prospective Observational Study
This study is trying to learn more about asthma by following 400 patients in China for two years to see how their condition changes and what factors might affect their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Chao Yang Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05937334 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a standardized asthma cohort of 400 patients in China, collecting baseline data through various diagnostic tests such as lung function tests and chest CT scans. Participants will be followed for at least two years to observe asthma outcomes and identify biomarkers that may predict these outcomes. The study will utilize an electronic data capture system and involve statistical analysis by a specialized work group from the Chinese Academy of Sciences. No investigational drugs will be administered, focusing instead on understanding the mechanisms of asthma pathogenesis.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who meet the 2023 GINA diagnostic criteria for asthma and can commit to a two-year follow-up.
Not a fit: Patients with severe lung diseases, recent surgeries, or other serious uncontrolled conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of asthma, potentially identifying biomarkers that help predict patient outcomes.
How similar studies have performed: Other studies have shown success in establishing asthma cohorts and identifying biomarkers, making this approach both relevant and promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 * Meet the 2023 edition of GINA asthma diagnostic criteria * Subjects must sign informed consent prior to study participation, participate in the study according to the protocol and follow up for 2 years Exclusion Criteria: * Suffering from other massive lung tissue destructive diseases such as severe bronchiectasis and tuberculosis * Severe pleural disease and/or sternal and rib lesions * Serious uncontrolled disease of other system * Thoracic or abdominal surgery in the past 3 months * Eye surgery in the past three months * Retina detachment * Myocardial infarction within the last 3 months * Hospitalized for heart disease within the past 3 months * Ongoing anti-tuberculosis treatment * Pregnancy or breast feeding
Where this trial is running
Beijing, Beijing Municipality
- Beijing Chao Yang Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Meishan Liu, M.D.
- Email: ccmuliumeishan@163.com
- Phone: 8613141403749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.